LAG 3 Validation Of Next Generation Checkpoint Pathways

Lag 3 Validation Of Next Generation Checkpoint Pathways-PDF Download

  • Date:12 Aug 2020
  • Views:3
  • Downloads:0
  • Pages:28
  • Size:1.96 MB

Share Pdf : Lag 3 Validation Of Next Generation Checkpoint Pathways

Download and Preview : Lag 3 Validation Of Next Generation Checkpoint Pathways


Report CopyRight/DMCA Form For : Lag 3 Validation Of Next Generation Checkpoint Pathways


Transcription:

Notice Forward Looking Statements, The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889. ASX PRR NASDAQ PBMD These slides have been prepared as a presentation aid only and the information they. contain may require further explanation and or clarification Accordingly these slides and the information they. contain should be read in conjunction with past and future announcements made by Prima BioMed and should not. be relied upon as an independent source of information Please refer to the Company s website and or the. Company s filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not. been independently verified No representation or warranty is made as to the accuracy completeness or reliability. of the information Any forward looking statements in this presentation have been prepared on the basis of a. number of assumptions which may prove incorrect and the current intentions plans expectations and beliefs about. future events are subject to risks uncertainties and other factors many of which are outside Prima BioMed s. control Important factors that could cause actual results to differ materially from assumptions or expectations. expressed or implied in this presentation include known and unknown risks Because actual results could differ. materially to assumptions made and Prima BioMed s current intentions plans expectations and beliefs about the. future you are urged to view all forward looking statements contained in this presentation with caution This. presentation should not be relied on as a recommendation or forecast by Prima BioMed Nothing in this. presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any. jurisdiction,Lymphocyte Activation Gene 3,LAG 3 or CD223. Genomic LAG 3 1 kb,L V V C C C Tm Cyt,4 IgSF domain transmembrane proteins. Same genomic organization,intron in D1 duplication event D1D2 vs D3D4. Close proximity on 12p13, Immunological mechanisms elicited at the tumour site.
by LAG 3 versus IL 12,sharing a common Th1 anti tumour immune pathway. 4 J Pathol 2005 205 82 91, Immunological mechanisms elicited at the tumour site. by LAG 3 versus IL 12,sharing a common Th1 anti tumour immune pathway. LAG 3 MHC class II interaction,LAG 3 blocking mAb,an immune checkpoint. LAG 3Ig fusion protein IMP321,an immune checkpoint.
LAG 3Ig fusion protein IMP321,an APC activator,primary MoA. First in class APC Activator,IMP321 LAG 3Ig,A soluble dimeric recombinant form of LAG 3 for. the activation of the APC network in the body,Very stable human protein with high affinity for. dendritic cells monocytes i e APC,Effectively tested as chemoimmunotherapy in. several indications,Extension to other indications possible by.
coupling with other first line chemotherapy,Can also be used at low doses as an adjuvant to. cancer vaccines,9 APC Antigen Presenting Cell, Soluble dimeric recombinant form of LAG 3Ig fusion protein. IMP321 binds,to MHC class II,DC monocytes,DC monocyte. activation,Leads to T cell,expansion and,proliferation. Highly efficacious in multiple animal models of cancer and infectious disease. Shown to be safe non immunogenic and efficacious in humans. At low doses can be used as a T cell adjuvant for cancer vaccines. IMP321 LAG 3Ig as an MHC class II agonist,primary MoA.
mDC hIgG1 negative control 4 hrs mDC 1 g ml LAG 3Ig 4 hrs. Monocyte derived DC mDC human blood monocytes are cultured. with GM CSF IL 4 for 5 days and are differentiated into immature DC. IMP321 Clinical Trials Overview,Protocol Patient Population Compound Status. healthy males IMP321 adjuvant Completed,healthy males IMP321 adjuvant Completed. metastatic renal cell carcinoma IMP321 monotherapy Completed. metastatic breast carcinoma IMP321 chemo immunotherapy Completed. disease free melanoma IMP321 adjuvant Completed,Phase I IIa. metastatic melanoma IMP321 adjuvant Completed,Phase I IIa. advanced pancreatic cancer IMP321 chemo immunotherapy Completed. Phase I II,melanoma IMP321 adjuvant Completed,Phase I IIa.
prostate carcinoma IMP321 adjuvant Completed,Rationale for combining chemotherapy. with IMP321 LAG 3Ig in breast cancer,A defect on APC function induces a lower. response to chemo, TLR4 dictates the efficacy of anti tumor chemotherapy. in humans Kaplan Meier estimates of time to, metastasis between two groups of patients bearing the. normal or mutated TLR4 alleles The time to,progression was analyzed in 280 women with.
nonmetastatic breast cancer with lymph node, involvement who were treated by surgery followed by. anthracycline based chemotherapy and local,irradiation. Nature Medicine 2007 13 1050 1059, In breast cancer patients who receive adjuvant chemotherapy the analysis of metastasis free survival. showed an overall significantly lower percentage of metastasis free patients in the group with mutated TLR4. The effect of the TLR4 mutation is to reduce antigen presenting cell function Such patients could not benefit. fully from the immunological component of chemotherapy i e the induction of cytotoxic CD8 T cell. responses to tumor antigens released by the dying tumor cells. A new field combination of chemo with a non specific. i e not a vaccine active immunotherapy,An APC activator like IMP321 given after. chemotherapy induces the APCs to mature,and transport the apoptotic cell death tumor.
antigenic debris to the lymph nodes for, presentation to the T cells Importantly a APC activator. concentration of only a few ng mL of IMP321,has been shown to be active in vitro on. APCs showing the great potency of IMP321,as an agonist of the immune system. Immune Checkpoint Modulation amp Combination Therapies April 13 2016 London UK LAG 3 Validation Of Next Generation Checkpoint Pathways ASX PRR NASDAQ PBMD Notice Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 ASX PRR NASDAQ PBMD These slides have been prepared as a presentation aid only and the

Related Books